BKM120 (NVP-BKM120, Buparlisib)

Catalog No.S2247

BKM120 (NVP-BKM120, Buparlisib) Chemical Structure

Molecular Weight(MW): 410.39

BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 34 Publications

3 Customer Reviews

  • After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. BKM120 (NVP-BKM120, Buparlisib) purchased from Selleck.

    One customer. BKM120 (NVP-BKM120, Buparlisib) purchased from Selleck.

  • Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. BKM120 (NVP-BKM120, Buparlisib) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MmGwR5l1d3SxeHnjJGF{e2G7 M3TLU|czKGh? MoTjSG1UVw>? NVizdXpzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=> Mkm1NlQ6ODB{Nk[=
DU145 Mn3CR5l1d3SxeHnjJGF{e2G7 MmTyO|IhcA>? NULxSZlxTE2VTx?= MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEyNQkGgcZV1[W62IIfpeIghT0l3MDDv[kAxNjByMESzOUDPxE1? Mn3yNlQ6ODB{Nk[=
A2780 NYfYVWVJS3m2b4TvfIlkKEG|c3H5 NIHmWW84OiCq M4TIXmROW09? NYjNUGdCS3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjN3IN88US=> MXOyOFkxODJ4Nh?=
U87MG MUTDfZRwfG:6aXOgRZN{[Xl? MVq3NkBp NVXQXYJYTE2VTx?= Mnr3R5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?= NIDyTIgzPDlyMEK2Oi=>
A2780 NVHoc2NqTnWwY4Tpc44hSXO|YYm= MV[xJIg> MV\EUXNQ MkO0TY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkC1OUDPxE1? M{\BZ|I1QTByMk[2
DU145 Mo\0SpVv[3Srb36gRZN{[Xl? M4W1fVEhcA>? MnjzSG1UVw>? M3XQOGlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBFXTF2NTDj[YxteyCqYYLic5JqdmdiTFvCNUBufXSjdHnvckB4cXSqIFXDOVAhd2ZiMD6wO|Mh|ryP NH;ZeVczPDlyMEK2Oi=>
A2780 M1vWVWZ2dmO2aX;uJGF{e2G7 M1v3VVEhcA>? M4nVcmROW09? M4qzS2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO|Qh|ryP MW[yOFkxODJ4Nh?=
MCF7 NX7UUJBJTnWwY4Tpc44hSXO|YYm= NGnUdHUyKGh? NEPYO4ZFVVOR NF;kcZlKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hf2m2aDDFR|UxKG:oIECuNUDPxE1? M4PMfFI1QTByMk[2
U87MG MV7GeY5kfGmxbjDBd5NigQ>? Mn\HNUBp NF2zPJZFVVOR NHTUW3RKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDFR|UxKG:oIECuNVMh|ryP NX3YOIVwOjR7MECyOlY>
A2780 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYW3NkBp MYrEUXNQ MXPFR|UxRTBwNUKg{txO MljWNlQ6ODB{Nk[=
SKMES-1 MV;DfZRwfG:6aXOgRZN{[Xl? MUmxJO69VQ>? MnrBO|IhcA>? NGTsPZVKdmS3Y3XzJINmdGxiZHXheIg> M3XmNFI3ODF|M{G4
H596 MX;GeY5kfGmxbjDBd5NigQ>? NF7pb2YyKM7:TR?= NIDKTWlKdXCjaYLzJINmdGxibXnndoF1cW:w NVvsc4ptOjZyMUOzNVg>
HCC2450 MmGySpVv[3Srb36gRZN{[Xl? NF6wOWoyKM7:TR?= NVe0elNXUW2yYXnyd{Bk\WyuIHnueoF{cW:w NHq3WW8zPjBzM{OxPC=>
A549 NVGxTnI{TnWwY4Tpc44hSXO|YYm= NULpU5NFPTByIH7N MoPGOFghcA>? MlLoSG1UVw>? MVHJcohq[mm2czDBb5Qh[WO2aY\heIlwdg>? MW[yOVk{PzJ7OR?=
A549 NWHJVFg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTVdVJnOSEQvF2= NHjJNVQ4OiCq MWPEUXNQ MVrJcohq[mm2czDj[YxtKGe{b4f0bC=> MknnNlU6Ozd{OUm=
H522 M1\wVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX1NUDPxE1? NGHwXJc4OiCq NET2[41FVVOR MmXFTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MnPuNlU6Ozd{OUm=
LNCaP M2\CemZ2dmO2aX;uJGF{e2G7 NWjQRYR6OSEQvF2= NFWyZ4NUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?= NV3WTWQ4OjV|NkC3PVk>
LNCaP95 NYnSWmxSTnWwY4Tpc44hSXO|YYm= M4jBcVEh|ryP M2C5T3N2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| M3zQU|I2OzZyN{m5
HCT-15 M33zWWFxd3Sxc3nzJGF{e2G7 NFjSW|EyOCEQvF2= MljVOFghcA>? MX\EUXNQ MoX0TY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUG1JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MYOyOVE2OjJ2NR?=
HCT-116 MYHBdI91d3OrczDBd5NigQ>? NXL2TpA1OTBizszN MojZOFghcA>? NHvTXYdFVVOR NInZWIJKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVE3KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= MoruNlUyPTJ{NEW=
NCI-H460 M3nzcmFxd3Sxc3nzJGF{e2G7 MljDNVAh|ryP Ml[2OFghcA>? MnrpSG1UVw>? MnfRTY5lfWOnczDhdI9xfG:|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NFrXUnEzPTF3MkK0OS=>
SKOV-3 M1PNRmFxd3Sxc3nzJGF{e2G7 M17FZlExKM7:TR?= MkTEOFghcA>? MnPiSG1UVw>? NEnRcYVKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCVS1;WMVMh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MmXUNlUyPTJ{NEW=
BSY-1 MnfXRZBwfG:|aYOgRZN{[Xl? M4nXZlExKM7:TR?= NFfEb|Y1QCCq M1ize2ROW09? NWLlbHEyUW6mdXPld{BieG:ydH;zbZMhcW5iQmPZMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M{T6XlI2OTV{MkS1
MKN-1 NV;LOZdISXCxdH;zbZMhSXO|YYm= NXvqfIhvOTBizszN NHG2ZVE1QCCq NH\pdpRFVVOR MWLJcoR2[2W|IHHwc5B1d3OrczDpckBOU05vMTDj[YxteyCqYYLic5VzcW6pIGDJT|NESSCqb4TzdI91KG23dHH0bY9v MYSyOVE2OjJ2NR?=
NCI-H522 NYTIdplTSXCxdH;zbZMhSXO|YYm= MUixNEDPxE1? NY\CS2tbPDhiaB?= NVnJSpR7TE2VTx?= M{XwNmlv\HWlZYOgZZBweHSxc3nz M2HocVI2OTV{MkS1
OVCAR-3 MoKyRZBwfG:|aYOgRZN{[Xl? M{TX[lExKM7:TR?= NF7INms1QCCq NX7KPY4zTE2VTx?= NIjaVXNKdmS3Y3XzJIFxd3C2b4Ppdy=> M3nSeFI2OTV{MkS1
HBC-5 M3zYZmFxd3Sxc3nzJGF{e2G7 M{TBXlExKM7:TR?= MYm0PEBp NXnEOIVtTE2VTx?= MWPJcoR2[2W|IHHwc5B1d3Orcx?= MlHiNlUyPTJ{NEW=
RXF-631L M{fnRWFxd3Sxc3nzJGF{e2G7 MnG4NVAh|ryP MWq0PEBp NX\kRWQ2TE2VTx?= M3XENGlv\HWlZYOgZZBweHSxc3nz MW[yOVE2OjJ2NR?=
MKN-45 NYPUVFZWSXCxdH;zbZMhSXO|YYm= NXLaRo1pOTBizszN M1\qUlQ5KGh? MoCxSG1UVw>? NWL3bWNiUW6mdXPld{BieG:ydH;zbZM> NYPkdXlHOjVzNUKyOFU>
BON-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW0OVAxKG6P MkX4NVAh\A>? NYTkdmxoTE2VTx?= M{HuSmlvcGmkaYTzJINmdGxiZ4Lve5Rp MmXRNlUxOjZ{OUK=
BON-1 M3K1NGZ2dmO2aX;uJGF{e2G7 M{Dn[FUxOCCwTR?= MlrYOEBp MnzzSG1UVw>? M13EVmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= NWrwNZFkOjVyMk[yPVI>
QGP-1 NYXLNFBSTnWwY4Tpc44hSXO|YYm= NUXCVJpYPTByIH7N M{XuUFQhcA>? NHrUfYZFVVOR MnW0TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= Mkj0NlUxOjZ{OUK=
Huh7 NEnxNVFHfW6ldHnvckBCe3OjeR?= NH\QRosyKM7:TR?= MlGyNUBp NXqzPWxlTE2VTx?= MV;Jcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>? M3fhUFI2ODB2NECz
BNL M1\zZ2Z2dmO2aX;uJGF{e2G7 MUixJO69VQ>? NFXUe4kyKGh? NXKxT3FlTE2VTx?= NWjyTVU6UW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFN4 MYGyOVAxPDRyMx?=
MDA-MB-175 M{fIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnizNUDPxE1? M{WyZ|Uh\A>? MXLEUXNQ NHvrPIFKSzVyPEGg{txO NUDneVd6OjR6N{m3PVY>
MDA-MB-134 NVvMUYZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSxJO69VQ>? M{\BeFUh\A>? MomySG1UVw>? MUPJR|UxRDFizszN M2TZclI1QDd7N{m2
HCC1500 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOxJO69VQ>? MmnLOUBl MoCzSG1UVw>? NGjD[IxKSzVyPEGg{txO MXGyOFg4QTd7Nh?=
EFM-19 NFHYWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7ZeotbOSEQvF2= MV61JIQ> NXi0Z482TE2VTx?= NVjsd4VwUUN3MEyxJO69VQ>? MVmyOFg4QTd7Nh?=
ZR-75-30 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmwNUDPxE1? M3HOcVUh\A>? NWPFe|RRTE2VTx?= MYjJR|UxRDFizszN NInWV5UzPDh5OUe5Oi=>
MDA-MB-361 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzq[HgyKM7:TR?= MmTyOUBl NHL3VpRFVVOR M3frc2lEPTB:MTFOwG0> NInzdIUzPDh5OUe5Oi=>
T-47D MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xJO69VQ>? MYm1JIQ> NXnJToZSTE2VTx?= NXizcWtwUUN3MEyxJO69VQ>? NH;3N2kzPDh5OUe5Oi=>
SK-BR-3 NWLiTVJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;qNUDPxE1? MUK1JIQ> MofHSG1UVw>? NIHEfZFKSzVyPEGg{txO NEnQWFUzPDh5OUe5Oi=>
UACC-732 NG\KfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm1NUDPxE1? NHrD[Vg2KGR? MojNSG1UVw>? M{DHdGlEPTB:MTFOwG0> MnPONlQ5Pzl5OU[=
BT-474 NEe4SlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DiW|Eh|ryP MXu1JIQ> M3;GN2ROW09? NGHLTHhKSzVyPEGg{txO NUDlW|JxOjR6N{m3PVY>
HCC202 NWDCfZlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vrOFEh|ryP NUDuNJNHPSCm MmjPSG1UVw>? M4DGNmlEPTB:MTFOwG0> Ml\yNlQ5Pzl5OU[=
MCF7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonHNUDPxE1? MYO1JIQ> NYC0eHFKTE2VTx?= NGLGXFNKSzVyPEGg{txO M37KU|I1QDd7N{m2
MDA-MB-415 M33GZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7FNUDPxE1? NInHN3g2KGR? M4WydGROW09? NWXyRpBqUUN3MEyxJO69VQ>? MYeyOFg4QTd7Nh?=
MDA-MB-453 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqxJO69VQ>? MUi1JIQ> MnLGSG1UVw>? MYfJR|UxRDFizszN Mn:zNlQ5Pzl5OU[=
ZR-75-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LRc|Eh|ryP NVzwb|FUPSCm NWmzU4VyTE2VTx?= NETKV3JKSzVyPEGg{txO NHzsV4wzPDh5OUe5Oi=>
HCC38 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXQeI4yKM7:TR?= NHq3Xpo2KGR? NV60[3M2TE2VTx?= MXzJR|UxRDFizszN NXjtc21pOjR6N{m3PVY>
HCC1419 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGxJO69VQ>? M2fRV|Uh\A>? MUPEUXNQ M{TVW2lEPTB:MTFOwG0> MlTSNlQ5Pzl5OU[=
UACC-812 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XG[|Eh|ryP NXrZO2VqPSCm M4fwTWROW09? MU\JR|UxRDFizszN MonxNlQ5Pzl5OU[=
HCC1187 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHkZW4yKM7:TR?= Mn\UOUBl M4LqdWROW09? NGTyRlJKSzVyPEGg{txO NULZ[5ZiOjR6N{m3PVY>
KPL-1 NG[5SFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTxNHF1OSEQvF2= NGrDNnc2KGR? M2e2OWROW09? NGPIclhKSzVyPEGg{txO MVGyOFg4QTd7Nh?=
SUM-225 M2O0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XUdFEh|ryP M1vJ[VUh\A>? NUO1R3k5TE2VTx?= NWHXWXJWUUN3MEyxJO69VQ>? MWeyOFg4QTd7Nh?=
EFM-192A NXzhV5J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHVUZJtOSEQvF2= M4\k[FUh\A>? NHT6NZpFVVOR M{f5cWlEPTB:MTFOwG0> MnGzNlQ5Pzl5OU[=
JIMT-1 NUnRTndZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFmzcY0yKM7:TR?= M2LQVFUh\A>? NWLhdG84TE2VTx?= M4nF[mlEPTB:MTFOwG0> NYjvWnp3OjR6N{m3PVY>
HCC1143 M2m3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i4XVEh|ryP M1\Db|Uh\A>? MXzEUXNQ M2DCSWlEPTB:MTFOwG0> M3fVe|I1QDd7N{m2
HCC2218 NHjS[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXybXB[OSEQvF2= NEPNV2M2KGR? Ml3TSG1UVw>? MVfJR|UxRDFizszN MnnpNlQ5Pzl5OU[=
MDA-MB-468 Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj2RYoxOSEQvF2= M2fYZ|Uh\A>? M4nBXWROW09? Ml7UTWM2ODxzIN88US=> NUjlO3d[OjR6N{m3PVY>
BT-20 Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LieVEh|ryP MmHVOUBl NYLadY11TE2VTx?= NXvBd3NIUUN3MEyxJO69VQ>? M2foOFI1QDd7N{m2
MDA-MB-435 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\MNIN3OSEQvF2= MV61JIQ> NXrlWo9yTE2VTx?= NX3ZU4NPUUN3MEyxJO69VQ>? NGP3cm8zPDh5OUe5Oi=>
BT-549 M1q2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7TNUDPxE1? MV[1JIQ> MX;EUXNQ MYDJR|UxRDFizszN NYr0W45sOjR6N{m3PVY>
HCC1806 NFHiWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Xse|Eh|ryP NGq4b|E2KGR? M2XIO2ROW09? NUX0PWZYUUN3MEyxJO69VQ>? M3X2b|I1QDd7N{m2
HCC1937 NWrRUldFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fNOVEh|ryP NVfJOmFqPSCm M2PLTGROW09? MVrJR|UxRDFizszN NEL3WGIzPDh5OUe5Oi=>
Hs578T NIHrOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexJO69VQ>? NFLPV2s2KGR? MkPMSG1UVw>? M{frN2lEPTB:MTFOwG0> Mn3RNlQ5Pzl5OU[=
LN18 NF7ZPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOyNEDPxE1? M2HCV|czKGh? NX7qUI1nTE2VTx?= MVrJR|UxRDVizszN NUfPT2x[OjR5NEGwO|Q>
LN229 NF\ZU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPlXmtpOjBizszN NYfFfmtoPzJiaB?= NUjOWm9NTE2VTx?= NGnQXYJKSzVyPEWg{txO NF32fYIzPDd2MUC3OC=>
LNZ308 NYS1PJk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf3OWIzOCEQvF2= M{Dyb|czKGh? NUPtToZbTE2VTx?= MWfJR|UxRDVizszN MWqyOFc1OTB5NB?=
T98G MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;VNlAh|ryP M{H1VVczKGh? MXXEUXNQ MnP5TWM2ODx3IN88US=> MUKyOFc1OTB5NB?=
U87 M4HJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\aNlAh|ryP MoCxO|IhcA>? NIC0SIhFVVOR NIjXdJBKSzVyPEWg{txO M17zOFI1PzRzMEe0
LN18 MlPqSpVv[3Srb36gRZN{[Xl? NVPoPZd1PSEQvF2= NX7K[2t2OjRiaB?= NF\HSoRFVVOR MmPsTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? MV6yOFc1OTB5NB?=
LNZ308 NEjyenhHfW6ldHnvckBCe3OjeR?= M1nidVUh|ryP Mn7NNlQhcA>? M3XINGROW09? NWXBbmJZUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MoTCNlQ4PDFyN{S=
Saos-2 NUXj[JJ7TnWwY4Tpc44hSXO|YYm= NYTiU5A4PTBizszN Ml;MOFghcA>? NHHpd2RKdmirYnn0d{Bk\WyuIHnueoF{cW:w MX[yOFczPzZ4MB?=
MG-63 M1\KUWZ2dmO2aX;uJGF{e2G7 NW\P[I5JPTBizszN NXHoN3dsPDhiaB?= MkLLTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? M3S0VVI1PzJ5Nk[w
SJSA-1 MXnGeY5kfGmxbjDBd5NigQ>? NH3meGE2OCEQvF2= MnG2OFghcA>? MUPJcohq[mm2czDj[YxtKGmwdnHzbY9v MUiyOFczPzZ4MB?=
Saos-2 M{LMTWZ2dmO2aX;uJGF{e2G7 M2DqWFUxKM7:TR?= NGLKb5M1QCCq M2e1[mlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> MVOyOFczPzZ4MB?=
MG-63 MYPGeY5kfGmxbjDBd5NigQ>? NH\kSoY2OCEQvF2= M{G5UlQ5KGh? M4P4dmlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> M2TTNVI1PzJ5Nk[w
SJSA-1 NFvGZ5FHfW6ldHnvckBCe3OjeR?= M17YUFUxKM7:TR?= Mn[5OFghcA>? NH3kTIlKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v NFS0U|kzPDd{N{[2NC=>
Saos-2 Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofvOVAh|ryP NH2zS|E1QCCq NVrFV4NpUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= Mni2NlQ4Ojd4NkC=
MG-63 NF;HPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrBOVAh|ryP NGTWfok1QCCq NF;jRldKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NHy4d|czPDd{N{[2NC=>
SJSA-1 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHVWIwzPTBizszN M3vpT|Q5KGh? Mkn6TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NFvvSIwzPDd{N{[2NC=>
FaDu NY\6XVBWTnWwY4Tpc44hSXO|YYm= M{DwPFUh|ryP NXz0UGQ1OjRiaB?= NXHD[|ZXTE2VTx?= M2n3RnJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NX;MbGZKOjR4M{GxOFc>
EMT6 NYrobIpqTnWwY4Tpc44hSXO|YYm= MUW1JO69VQ>? NEfDOZkzPCCq MU\EUXNQ MVXS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= NF\NPW0zPDZ|MUG0Oy=>
HCT116 MlX3SpVv[3Srb36gRZN{[Xl? MYq1JO69VQ>? MlPzNlQhcA>? NUDOcHZ[TE2VTx?= NVHEe|lyWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> MWOyOFY{OTF2Nx?=
U87 NWjKOmtGTnWwY4Tpc44hSXO|YYm= MVG1JO69VQ>? M1OxV|I1KGh? MkD3SG1UVw>? NHvsfJNT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> Mk\yNlQ3OzFzNEe=
GBM NIrJRnpCeG:ydH;zbZMhSXO|YYm= MYey{txO M1fNNVQ5cA>? M3nOR2ROW09? MlvNbY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=> NHuxS4IzPDVyMES5Ni=>
BON MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnmNU02|ryP NVnUWohxPzKq MV\k[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;u NW\GZYtOOjR2NEO1NlM>
BON MULBdI9xfG:|aYOgRZN{[Xl? NIGydlcyNTYQvF2= NUCzNnZzOjSq M3SxUYlv[3KnYYPld{BieG:ydH;zbZM> M{LnR|I1PDR|NUKz
H1975 NVmyRoFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn0RYpQOC5|LUmuOu69VQ>? MoPlO|Jp NWHMPXdYTE2VTx?= MVTJR|UxRTFwM{i1{txO NH3aOW4zPDN|N{i0Oi=>
H1975 MYrBdI9xfG:|aYOgRZN{[Xl? MW[y{txO M2DlSVI1cA>? MVrEUXNQ M2P1eolv[3KnYYPld{BieG:ydH;zbZMhemG2ZTDzbYdvcW[rY3HueIx6 Mo\jNlQ{Ozd6NE[=
T-ALL M3;xNWFxd3C2b4Ppd{BCe3OjeR?= NXnWc5hm[mW2d3XlckAyNjRiYX7kJFUvOyCvTTDheEAzPGhiYX7kJFAvQSCjbnSgOU42KG2PIHH0JFQ5cCCrbjDkbYZn\XKnboSgZ4VtdCCuaX7l NUfU[Yx[OjRib4KgOFhp NUnj[XJZTE2VTx?= NIfhVFli\m[nY4TzJJRp\SCSSUPLJJBifGi5YYmgbY4hXC2DTFygZ4VtdCCuaX7ldy=> M2XjTVI1OzFyN{O2
BCR-ABL MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnqdHZUOC5{NT2xNO69VQ>? NXWxZ|lVPGR? MlPmd4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>? NEf3fnAzPDJ2NE[xNi=>
LC-1/SQSF M2ThcGZ2dmO2aX;uJGF{e2G7 NH3nZos{|ryP NX[0XXdyOjSq M3PsXGROW09? MlHS[IVkemWjc3WgUnJHOiCycn;0[YlvKGyndnXs NFHEN48zOzl6MEC5Ny=>
Primary CLL cells MVXBdI9xfG:|aYOgRZN{[Xl? MVWxMVEx|ryP NULZO2tVPDiq M3XINIlv\HWlZYOgZZBweHSxc3nzJIlvKEOOTDDj[YxteyCrbnTldIVv\GWwdDDv[kBxem:pbn;zeIlkKG2jcnvldpM> MonzNlM5PTB6MEe=
Primary CLL cells M174SWtqdmG|ZTDBd5NigQ>? NEH2NFQz|ryP M3zNPFMxdWmw Mkn5[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? M2LHeVI{QDVyOEC3
Primary CLL cells NG[wNXlEgXSxdH;4bYMhSXO|YYm= NIrPT5cz|ryP NHLzeFMzPGh? NWTmWVJjcW6mdXPld{Bk\WyuIHP5eI91d3irY3n0fS=> MoPxNlM5PTB6MEe=
human NSCLC cell lines MnziRZBweHSxc3nzJGF{e2G7 MV2wMlEzPS12zszN NFPMRZkzPGh? M3yxO2ROW09? MUfJR|UxeyC{YX7n[ZMh\nKxbTCwMlQuOs7:TR?= NWTJcZNFOjN3NkK0O|I>
human HCC cell lines NILj[HFE\WyuII\pZYJqdGm2eTDhd5NigQ>? NH\UbWcxNjByNT2x{txO MnLROFhp NXPo[JRsUUN3ME2x{txO Mn3lNlM1QDl7OUm=
Huh7 NI[3WYxMcW6jc3WgRZN{[Xl? NIrGTG4y|ryP MWi0PIg> NUTwcnR{e2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1 NXTudYpsOjN2OEm5PVk>
SK-HEP1 NFG5cYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rNZlEuOjEQvF2= NXvBNJQ5PzKq NUD4ZmtLTE2VTx?= M2q1d2lEPTExvKyx{txO NFLWSogzOzR5OUGzOi=>
786-0 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxMVIx|ryP NEPQWHc4Omh? MlTESG1UVw>? NYrF[mEzUUN3MP-8oFHPxE1? NGLDd20zOzR5OUGzOi=>
JVM2 MlXTR5l1d3SxeHnjbZR6KGG|c3H5 MkTwNE4zNTJyzszN M{XQO|czcA>? NVnITFNpTE2VTx?= MWfJR|UxRTBwOd88US=> MX2yN|I{QDZ|OR?=
EHEB MWjDfZRwfG:6aXPpeJkh[XO|YYm= MXSwMlIuOjEQvF2= NEeyUlY4Omh? MmTDSG1UVw>? NEXPbGRKSzVyPUCuO:69VQ>? NGS4[nozOzJ|OE[zPS=>
MEC2 MojDR5l1d3SxeHnjbZR6KGG|c3H5 MoL0NE4zNTJyzszN MXe3Nog> MkfiSG1UVw>? MWfJR|UxRTBwN988US=> MXSyN|I{QDZ|OR?=
primary B-CLL lymphocytes NGrlemdCeG:ydH;zbZMhSXO|YYm= Mn;4TWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? MUKyOIg> MYDEUXNQ M{XtO2lEPTExvKyz{txOKG[xcjDhcIwheGG2aXXueJM> MUOyN|I{QDZ|OR?=
primary B-CLL lymphocytes MnroT4lv[XOnIFHzd4F6 M4fGWGlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? Mn\wNlRp MoLobY5pcWKrdIOgdFcxWz[NID[gOGUuSlBzIHX4dJJme3Orb36= NHnTXmozOzJ|OE[zPS=>
human NSCLC M1ntZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37XRVAvPS1{zszN M3v0SVczcA>? NWX3XW9NUUN3ME2x{txO MW[yNlc5OTN7Mx?=
human NSCLC M1vETGtqdmG|ZTDBd5NigQ>? MX[x{txO MmPDNlRp NGfPTZNqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 NGDtd2EzOjd6MUO5Ny=>
Y1 cell line NWnFT4lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fwSFAvOc7:TT:x{txO NVuy[2k6OjSq MoLoSG1UVw>? MWTpcohq[mm2czC2NQ+9jSClZXzsJJZq[WKrbHn0fUBqdiCPeXOtV4N1ei22cnHud4Zm[3SnZDDj[Yxtew>? MW[yNlY6OjlyNB?=
PIK3CA-mutant MCF7 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPROmxMT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= NEXwXpI4Omh? MWDHTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO|NvVQ>? NVHtNpJuOjJ4NUO5Olc>
PIK3CA-mutant MCF7 MUfLbY5ie2ViQYPzZZk> MXjJR|UxRTFzNNMxN45O MYS3Nog> MUXJR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| MoTFNlI3PTN7Nke=
MCF7-myr-Akt M4P6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? NXLIXHpLPzKq M3njbWdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P NYjQOWhtOjJ4NUO5Olc>
colon cancer cell lines NIXucJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK1dmkxNTFyzszN MkfnO|Jp NHXQWJNFVVOR MXTJR|UxRTIQvF2= NWX1cZN2OjJ3NEO4OVc>
gastric cancer cell lines NGS3ZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r3clAuOTEQvF2= MUe3Nog> NXzuT5pDTE2VTx?= NWHOcm1qUUN3ME2yMVXPxE1? MnHHNlI2PDN6NUe=
HCT-116/HT-29/MKN-45 MmT1RZBweHSxc3nzJGF{e2G7 Ml\0Nu69VQ>? NH[2VJA1QGh? M{XLOpNpcW[2IHnuJGczKHCqYYPl M4\NV|IzPTR|OEW3
HT-29 and HCT-116 MVnDZZNx[XOnIHHzd4F6 NFTWd|E2|ryP NEDWNowzPGh? NIfYWXBqdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm= M3:1elIzPTR|OEW3
MM cell lines MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOxNO69VQ>? M1vod|I1cA>? NWXvZ2RFTE2VTx?= NHe0ZmdKSzVyII\hdolmeyCjbX;u[{BlcW[oZYLlcpQh[2WubDDsbY5meyCrbjD0bY1mKGGwZDDkc5NmKGSncHXu[IVv[2V? MViyNlIxPzR6NR?=
ARP-1 NFTsXlNCeG:ydH;zbZMhSXO|YYm= Mmm4NVDPxE1? M1:zTFI1cA>? NUKwdnQyTE2VTx?= MU\pcoR2[2W|IF3NJINmdGxiYYDvdJRwe2m|IITodo92\2hiY3HzdIF{\SCjY4TpeoF1cW:w Mn7sNlIzODd2OEW=
SNU-601 NHXxd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:3Nog> NVvybVBDTE2VTx?= NFv0Z|FKSzVyPUCuPFE3yrFyLkC2N:69VQ>? NGKyPFAzOjF3OUixOC=>
SNU-1 MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke3O|Jp MWHEUXNQ MljuTWM2OD1zLkC4NuKyOC5yMklOwG0> MXmyNlE2QThzNB?=
SNU-668 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTW[|Y4Omh? NH7PdZZFVVOR Ml3sTWM2OD1zLkW3PeKyOC5yN{VOwG0> NE\sTWQzOjF3OUixOC=>
AGS NFL4NYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf0O|Jp M4PxN2ROW09? MWnJR|UxRTFwN{G0xtExNjFzN988US=> MnfHNlIyPTl6MUS=
SNU-216 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHnO|Jp NFr6WHFFVVOR NXHqWnR4UUN3ME2yMlY6OsLzMD6wPFLPxE1? NYXuNplqOjJzNUm4NVQ>
SNU-5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq1O|Jp Mn7SSG1UVw>? M4XPcWlEPTB;MT6zOVHDuTBwMEmx{txO NH2wSlQzOjF3OUixOC=>
SNU-638 NFHXZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXVN2I4Omh? Mln1SG1UVw>? NHvRVFJKSzVyPUKuNlgzyrFyLkC1N:69VQ>? MnK3NlIyPTl6MUS=
SNU-16 NXq3WJpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVu3Nog> NXvaVXplTE2VTx?= M2n6U2lEPTB;MT61O|PDuTBwMECx{txO NGDreGczOjF3OUixOC=>
SNU-484 M2SxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3Nog> MUTEUXNQ NHzhUpBKSzVyPUGuO|I5yrFyLkC0Oe69VQ>? NFKyVm8zOjF3OUixOC=>
SNU-620 NGXENJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK3Nog> M4jh[GROW09? NFL2bXFKSzVyPUKuPVM6yrFyLkCwNe69VQ>? NWj1[VZvOjJzNUm4NVQ>
SNU-719 M1LCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDVO|Jp NYHqV3pXTE2VTx?= MYnJR|UxRTNwMEO3xtExNjB|Mt88US=> M{mzUVIzOTV7OEG0
glioma cell lines NXnwZXFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTTc2l4PzKq MnywTWM2OD1zLUNOwG0> MW[yNlA3PTB6MB?=
U87 M2D2RWFxd3C2b4Ppd{BCe3OjeR?= M2DQR|LPxE1? NF23VVE4Omh? MlfNbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCjbnSgZ4xm[X[nZDDQRXJRKGGwZDDjZZNx[XOnLUO= NXnBeYJqOjJyNkWwPFA>

... Click to View More Cell Line Experimental Data

In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay
+ Expand

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research
+ Expand
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water <1 mg/mL
In vivo 0.5% CMC Na 6 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756247 Not yet recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01971489 Withdrawn Adult Solid Neoplasm|Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) September 2015 Phase 1
NCT02452294 Recruiting Malignant Melanoma|Metastases University Hospital Tuebingen|University Hospital Dresden July 2015 Phase 2
NCT02303041 Active, not recruiting Basal Cell Carcinoma of the Skin|Nevoid Basal Cell Carcinoma Syndrome|Recurrent Skin Cancer Anne Chang|National Cancer Institute (NCI)|Stanford University February 2015 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy BKM120 (NVP-BKM120, Buparlisib) | BKM120 (NVP-BKM120, Buparlisib) supplier | purchase BKM120 (NVP-BKM120, Buparlisib) | BKM120 (NVP-BKM120, Buparlisib) cost | BKM120 (NVP-BKM120, Buparlisib) manufacturer | order BKM120 (NVP-BKM120, Buparlisib) | BKM120 (NVP-BKM120, Buparlisib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID